SCHEDULE 13G/A: Douglas K. Bratton and Affiliated Entities Report 11.1% Beneficial Ownership in Aquestive Therapeutics

Douglas K. Bratton and a group of affiliated investment entities have filed an updated Schedule 13G, disclosing a combined beneficial ownership of 11.1% in Aquestive Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Douglas K. Bratton (DKB) and a group of affiliated entities, including MonoLine Rx II, L.P., MonoLine Rx III, L.P., MonoLine Rx, L.P., MonoLine Partners, L.P., and MonoSol Rx Genpar, L.P., collectively reported beneficial ownership of Aquestive Therapeutics, Inc. common stock.
• As of December 31, 2024, Douglas K. Bratton is deemed to be the beneficial owner of an aggregate of 10,077,434 shares, representing approximately 11.1% of the outstanding common stock.
• DKB's reported ownership includes 10,023,384 shares over which he has sole voting and dispositive power.
• This 10,023,384 figure comprises 9,810,958 shares controlled through Bratton Inc. (general partner of Genpar and Bratton Capital) and 212,426 shares owned directly by DKB or by family trusts and entities.
• The total aggregate amount of 10,077,434 shares also includes 54,050 shares that DKB has the right to acquire under vested director stock options.
• Individual beneficial ownership percentages for the affiliated entities are: MonoLine Rx II, L.P. (3.8% or 3,468,747 shares), MonoLine Rx III, L.P. (2.9% or 2,657,943 shares), MonoLine Rx, L.P. (1.9% or 1,688,639 shares), MonoLine Partners, L.P. (2.1% or 1,948,578 shares), and MonoSol Rx Genpar, L.P. (0.1% or 47,051 shares).
• Bratton Capital Management L.P. is deemed to beneficially own approximately 10.7% (9,763,907 shares) and Bratton Capital Inc. is deemed to beneficially own approximately 10.8% (9,810,958 shares) due to their roles as general partners within the ownership structure.
• The filing explicitly states that DKB disclaims beneficial ownership of 2,727 shares owned by his spouse.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance data that would indicate a positive or negative sentiment. It is neutral.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of significant ownership by an investor group in a publicly traded biotechnology or pharmaceutical company, Aquestive Therapeutics, Inc. It reflects a substantial, long-term stake, which is common for institutional investors or individuals with a strategic interest in a company.

Related Party Transactions

• The filing details the interconnected ownership structure where Douglas K. Bratton, through Bratton Inc. and Bratton Capital Management L.P., controls various MonoLine entities, which collectively hold shares in Aquestive Therapeutics. This structure indicates related party control over the reported beneficial ownership.

Stakeholder Impact

• Shareholders: The disclosure of a significant 11.1% stake by Douglas K. Bratton and his affiliated entities indicates a substantial and potentially influential shareholder presence, which could impact corporate governance and strategic decisions.

Key Dates

Keywords

Aquestive Therapeutics, Douglas K. Bratton, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Institutional Ownership, Shareholder Disclosure, AQST